These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 27613121)

  • 1. Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.
    Órpez-Zafra T; Pavía J; Hurtado-Guerrero I; Pinto-Medel MJ; Rodriguez Bada JL; Urbaneja P; Suardíaz M; Villar LM; Comabella M; Montalban X; Alvarez-Cermeño JC; Leyva L; Fernández Ó; Oliver-Martos B
    Mult Scler; 2017 Jun; 23(7):937-945. PubMed ID: 27613121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of an ELISA for quantification of soluble IFN-β receptor: assessment in multiple sclerosis.
    Órpez-Zafra T; Pavía J; Pinto-Medel MJ; Hurtado-Guerrero I; Rodriguez-Bada JL; Martín Montañez E; Fernández Ó; Leyva L; Oliver-Martos B
    Bioanalysis; 2015; 7(22):2869-80. PubMed ID: 26571364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment.
    Aliaga-Gaspar P; Hurtado-Guerrero I; Ciano-Petersen NL; Urbaneja P; Brichette-Mieg I; Reyes V; Rodriguez-Bada JL; Alvarez-Lafuente R; Arroyo R; Quintana E; Ramió-Torrentà L; Alonso A; Leyva L; Fernández O; Oliver-Martos B
    Front Immunol; 2021; 12():778204. PubMed ID: 34975865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
    González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant soluble IFN receptor (sIFNAR2) exhibits intrinsic therapeutic efficacy in a murine model of Multiple Sclerosis.
    Suardíaz M; Clemente D; Marin-Bañasco C; Orpez T; Hurtado-Guerrero I; Pavía J; Pinto-Medel MJ; De Castro F; Leyva L; Fernández O; Oliver B
    Neuropharmacology; 2016 Nov; 110(Pt A):480-492. PubMed ID: 27452720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta.
    Hussien Y; Sanna A; Söderström M; Link H; Huang YM
    Mult Scler; 2004 Feb; 10(1):16-25. PubMed ID: 14760948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
    Johnson BH; Bonafede MM; Watson C
    CNS Drugs; 2015 Jun; 29(6):503-10. PubMed ID: 26113055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of interferon and glatiramer acetate on cytokine patterns in multiple sclerosis patients.
    Ganji A; Monfared ME; Shapoori S; Nourbakhsh P; Ghazavi A; Ghasami K; Mosayebi G
    Cytokine; 2020 Feb; 126():154911. PubMed ID: 31731047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
    Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
    Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies.
    McKay FC; Gatt PN; Fewings N; Parnell GP; Schibeci SD; Basuki MA; Powell JE; Goldinger A; Fabis-Pedrini MJ; Kermode AG; Burke T; Vucic S; Stewart GJ; Booth DR
    Clin Immunol; 2016 Feb; 163():96-107. PubMed ID: 26762769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate.
    Healy BC; Glanz BI; Zurawski JD; Mazzola M; Chitnis T; Weiner HL
    J Neurol Sci; 2018 Nov; 394():127-131. PubMed ID: 30248571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis.
    Sternberg Z; Leung C; Sternberg D; Yu J; Hojnacki D
    Cardiovasc Ther; 2014 Apr; 32(2):33-9. PubMed ID: 24119301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Draganaova-Filipova MN; Mateva NG; Miteva LD; Stanilova SA
    Scand J Clin Lab Invest; 2017 Jul; 77(4):283-288. PubMed ID: 28319417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b.
    Brown RA; Narayanan S; Stikov N; Cook S; Cadavid D; Wolansky L; Arnold DL
    Neurology; 2016 Aug; 87(9):905-11. PubMed ID: 27473139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate.
    Rojas-Morales E; Santos-López G; Hernández-Cabañas S; Arcega-Revilla R; Rosas-Murrieta N; Jasso-Miranda C; El-Kassis EG; Reyes-Leyva J; Sedeño-Monge V
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis.
    Petersen ER; Søndergaard HB; Oturai AB; Jensen P; Sorensen PS; Sellebjerg F; Börnsen L
    Mult Scler Relat Disord; 2016 Nov; 10():66-72. PubMed ID: 27919501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
    Alexander JS; Harris MK; Wells SR; Mills G; Chalamidas K; Ganta VC; McGee J; Jennings MH; Gonzalez-Toledo E; Minagar A
    Mult Scler; 2010 Jul; 16(7):801-9. PubMed ID: 20621951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab reduces serum pro-angiogenic activity in MS patients.
    Iaffaldano P; Ribatti D; Trojano M
    Neurol Sci; 2018 Apr; 39(4):725-731. PubMed ID: 29441483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
    Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P
    Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.